Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.79 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30518356 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| SCHEMBL16041166 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| SCHEMBL16041168 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| SCHEMBL29478448 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| SCHEMBL16042678 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| SCHEMBL29478430 | 0.95 | ROCK2 (0.90) | ROCK2ROCK1MYLK4 | |
| SCHEMBL16040143 | 0.95 | ROCK2 (0.90) | ROCK2ROCK1MYLK4 | |
| SCHEMBL16040142 | 0.95 | ROCK2 (0.90) | ROCK2ROCK1MYLK4 | |
| SCHEMBL13074858 | 0.90 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| SCHEMBL24336110 | 0.89 | ROCK2 (0.81) | ROCK2ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220088000-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2022-03-24 | — | — | US | claimed |
| CN-110396085-B | Combination therapy | 爱尔康公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4335507-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117050013-A | Mono (acid) salts of 6-aminoisoquinolines and use thereof | 爱瑞制药公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-111936139-B | Mono (acid) salts of 6-aminoisoquinolines and use thereof | 爱瑞制药公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4218759-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088000-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885MYLK4 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.